Enantioselective pharmacokinetics and cardiovascular effects of nebivolol in L-NAME hypertensive rats

Hypertension Research

Volumn 37, Issue 3, 2014, Pages 194-201

  Bertera, Facundo Martín ^a   Del Mauro, Julieta Sofía ^a   Lovera, Valeria ^a   Chiappetta, Diego ^a   Polizio, Ariel Héctor ^a   Taira, Carlos Alberto ^a   Höcht, Christian ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

blood pressure variability; enantioselective pharmacokinetics; L NAME hypertension; nebivolol; spectral analysis

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; N(G) NITROARGININE METHYL ESTER; NEBIVOLOL; PROPRANOLOL; TAP WATER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERIAL BLOOD; ARTICLE; BLOOD PRESSURE VARIABILITY; BLOOD SAMPLING; CARDIOVASCULAR EFFECT; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG FORMULATION; ENANTIOSELECTIVITY; HYPERTENSION; LIQUID CHROMATOGRAPHY; MALE; NONHUMAN; RAT;

ADRENERGIC BETA-ANTAGONISTS; ANIMALS; AREA UNDER CURVE; BENZOPYRANS; BLOOD PRESSURE; CHEMISTRY, PHARMACEUTICAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; ETHANOLAMINES; HEART RATE; HEMODYNAMICS; HYPERTENSION; INJECTIONS, INTRAVENOUS; MALE; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE TYPE I; RATS; RATS, WISTAR; STEREOISOMERISM;

EID: 84895834430     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2013.140     Document Type: Article

References (44)

1. Vanhoutte PM, Gao Y. Beta blockers, nitric oxide, and cardiovascular disease. Curr Opin Pharmacol 2013; 13: 265-273.
2. Gao Y, Vanhoutte PM. Nebivolol: an endothelium-friendly selective b1-adrenoceptor blocker. J Cardiovasc Pharmacol 2012; 59: 16-21.
3. Parati G, Ochoa JE, Lombardi C, Bilo G. Assessment and management of blood-pressure variability. Nat Rev Cardiol 2013; 10: 143-155.
4. Su DF, Miao CY. Blood pressure variability and organ damage. Clin Exp Pharmacol Physiol 2001; 28: 709-715.
5. Rothwell PM. Does blood pressure variability modulate cardiovascular risk? Curr Hypertens Rep 2011; 13: 177-186.
6. Schutte AE, Schutte R, Huisman HW, van Rooyen JM, Fourie CM, Malan NT, Malan L. Blood pressure variability is significantly associated with ECG left ventricular mass in normotensive Africans: the SABPA Study. Hypertens Res 2011; 34: 1127-1134.
7. Schillaci G, Pucci G, Parati G. Blood pressure variability: an additional target for antihypertensive treatment? Hypertension 2001; 58: 133-135.
8. Fortepiani LA, Ortíz MC, Atucha NM, García-Estañ J. Nebivolol ameliorates nitric oxide deficient hypertension. Scientific World Journal 2002; 2: 1676-1684.
9. Di Verniero CA, Bertera F, Buontempo F, Bernabeu E, Chiappetta D, Mayer MA, Bramuglia GF, Taira CA, Höcht C. Enantioselective pharmacokinetic- pharmacodynamic modelling of carvedilol in a N-nitro-l-arginine methyl ester rat model of secondary hypertension. J Pharm Pharmacol 2010; 62: 890-900.
10. Bernátová I, Pechánová O, Pelouch V, Simko F. Regression of chronic L-NAME-treatment-induced left ventricular hypertrophy: effect of captopril. J Mol Cell Cardiol 2000; 32: 177-185.
11. Aimone LD. Overview of pharmacokinetics. Curr Protoc Pharmacol 2005; 7: 1-26.
12. Pladys P, Lahaie I, Cambonie G, Thibault G, Le NL, Abran D, Nuyt AM. Role of brain and peripheral angiotensin II in hypertension and altered arterial baroreflex programmed during fetal life in rat. Pediatr Res 2004; 55: 1042-1049.
13. Souza HC, Martins-Pinge MC, Dias da Silva VJ, Borghi-Silva A, Gastaldi AC, Blanco JH, Tezini GC. Heart rate and arterial pressure variability in the experimental renovascular hypertension model in rats. Auton Neurosci 2008; 139: 38-45.
14. Gibaldi M, Perrier D. Pharmacokinetics, 2nd edn. Marcel Dekker, New York, 1982.
15. Moningka NC, Tsarova T, Sasser JM, Baylis C. Protective actions of nebivolol on chronic nitric oxide synthase inhibition-induced hypertension and chronic kidney disease in the rat: a comparison with angiotensin II receptor blockade. Nephrol Dial Transplant 2012; 27: 913-920.
16. Ribeiro MO, Antunes E, de Nucci G, Lovisolo SM, Zatz R. Chronic inhibition of nitric oxide synthesis. A new model of arterial hypertension. Hypertension 1992; 20: 298-303.
17. Terao N, Shen DD. Alterations in serum protein binding and pharmacokinetics of l-propranolol in the rat elicited by the presence of an indwelling venous catheter. J Pharmacol Exp Ther 1983; 227: 369-375.
18. Van Peer A, Snoeck E, Woestenborghs R, Van de Velde V, Mannens G, Meuldermans W, Heykants J. Clinical pharmacokinetics of nebivolol. Drug Invest 1992; 3: 25-30.
19. Bertera FM, Del Mauro JS, Polizio AH, Chiappetta D, Taira CA, Höcht C. Effect of nebivolol on beat-to-beat and short-term blood pressure variability in spontaneously hypertensive rats. Naunyn Schmiedebergs Arch Pharmacol 2012; 385: 833-843.
20. Van de Water A, Janssens W, Van Neuten J, Xhonneux R, De Cree J, Verhaegen H, Reneman RS, Janssen PA. Pharmacological and hemodynamic profile of nebivolol, a chemically novel, potent, and selective beta 1-adrenergic antagonist. J Cardiovasc Pharmacol 1988; 11: 552-563.
21. Höcht C, Di Verniero C, Opezzo JA, Bramuglia GF, Taira CA. Pharmacokinetic-pharmacodynamic (PK-PD) modeling of cardiovascular effects of metoprolol in spontaneously hypertensive rats: a microdialysis study. Naunyn Schmiedebergs Arch Pharmacol 2006; 373: 310-318.
22. Bertera FM, Del Mauro JS, Chiappetta D, Polizio AH, Buontempo F, Taira CA, Höcht C. Enantioselective pharmacokinetic and pharmacodynamic properties of carvedilol in spontaneously hypertensive rats: focus on blood pressure variability. Naunyn Schmie-debergs Arch Pharmacol 2012; 385: 325-335.
23. Kuroedov A, Cosentino F, Lüscher TF. Pharmacological mechanisms of clinically favorable properties of a selective beta1-adrenoceptor antagonist, nebivolol. Cardiovasc Drug Rev 2004; 22: 155-168.
24. Himmelmann A, Hedner T, Snoeck E, Lundgren B, Hedner J. Haemodynamic effects and pharmacokinetics of oral d-and l-nebivolol in hypertensive patients. Eur J Clin Pharmacol 1996; 51: 259-264.
25. Biancardi VC, Bergamaschi CT, Lopes OU, Campos RR. Sympathetic activation in rats with L-NAME-induced hypertension. Braz J Med Biol Res 2007; 40: 401-408.
26. Campbell DJ. L-NAME hypertension: trying to fit the pieces together. J Hypertens 2006; 24: 33-36.
27. Zanchi A, Schaad NC, Osterheld MC, Grouzmann E, Nussberger J, Brunner HR, Waeber B. Effects of chronic NO synthase inhibition in rats on renin-angiotensin system and sympathetic nervous system. Am J Physiol 1995; 268: H2267-H2273.
28. Sander M, Hansen PG, Victor RG. Sympathetically mediated hypertension caused by chronic inhibition of nitric oxide. Hypertension 1995; 26: 691-695.
29. Yan W, Sheng ZM, Yu L. Nebivolol treatment improves resistant arterial function and reduces ventricular hypertrophy and angiotensin II in spontaneously hypertension rats. J Renin Angiotensin Aldosterone Syst 2013; 14: 146-155.
30. Varagic J, Ahmad S, Voncannon JL, Moniwa N, Simington SW Jr, Brosnihan BK, Gallagher PE, Habibi J, Sowers JR, Ferrario CM. Nebivolol reduces cardiac angiotensin II, associated oxidative stress and fibrosis but not arterial pressure in salt-loaded spontaneously hypertensive rats. J Hypertens 2012; 30: 1766-1774.
31. Chiladakis JA, Georgiopoulou E, Alexopoulos D. Autonomic effects of nebivolol versus atenolol in healthy subjects. Cardiovasc Drugs Ther 2004; 18: 469-473.
32. Sacco G, Evangelista S, Criscuoli M, Goso C, Bigioni M, Binaschi M, Manzini S, Maggi CA. Involvement of nitric oxide in both central and peripheral haemo-dynamic effect of D/L-nebivolol and its enantiomers in rats. Eur J Pharmacol 2005; 511: 167-174.
33. Stauss HM. Identification of blood pressure control mechanisms by power spectral analysis. Clin Exp Pharmacol Physiol 2007; 34: 362-388.
34. Janssen BJ, Oosting J, Slaaf DW, Persson PB, Struijker-Boudier HA. Hemodynamic basis of oscillations in systemic arterial pressure in conscious rats. Am J Physiol 1995; 269: H62-H71.
35. Fazan R Jr, Huber DA, Silva CA, Dias da Silva VJ, Salgado MC, Salgado HC. Sildenafil acts on the central nervous system increasing sympathetic activity. J Appl Physiol 2008; 104: 1683-1689.
36. Webb AJ, Fischer U, Mehta Z, Rothwell PM. Effects of antihypertensive- drug class on interindividual variation in blood pressure and risk of stroke: a systematic review and meta-analysis. Lancet 2010; 375: 906-915.
37. Rothwell PM, Howard SC, Dolan E, O'Brien E, Dobson JE, Dahlöf B, Poulter NR, Sever PSASCOT-BPLA and MRC Trial Investigators. Effects of beta-blockers and calcium channel blockers on within-individual variability in blood pressure and risk of stroke. Lancet Neurol 2010; 9: 469-480.
38. Höcht C, Bertera FM, Mayer MA, Taira CA. Issues in drug metabolism of major antihypertensive drugs: beta-blockers, calcium channel antagonists and angiotensin receptor blockers. Expert Opin Drug Metab Toxicol 2010; 6: 199-211.
39. Höcht C, Bertera FM, Taira CA. Importance of blood pressure variability in the assessment of cardiovascular risk and benefits of antihypertensive therapy. Expert Rev Clin Pharmacol 2010; 3: 617-621.
40. Webb AJ, Fischer U, Rothwell PM. Effects of b-blocker selectivity on blood pressure variability and stroke: a systematic review. Neurology 2011; 77: 731-737.
41. Bertera FM, Del Mauro JS, Lovera V, Chiappetta D, Héctor Polizio A, Alberto Taira C, Höcht C. Acute effects of third generation b-blockers on short-term and beat-to-beat blood pressure variability in sinoaortic-denervated rats. Hypertens Res 2013; 36: 349-355.
42. Wang DS, Xie HH, Shen FM, Cai GJ, Su DF. Blood pressure variability, cardiac baroreflex sensitivity and organ damage in experimentally hypertensive rats. Clin Exp Pharmacol Physiol 2005; 32: 545-552.
43. Blanc J, Ponchon P, Laude D, Elghozi JL, Jover B. Blood pressure variability in established L-NAME hypertension in rats. J Hypertens 1999; 17: 1527-1534.
44. Gouédard O, Blanc J, Gaudet E, Ponchon P, Elghozi JL. Contribution of the renin-angiotensin system to short-term blood pressure variability during blockade of nitric oxide synthesis in the rat. Br J Pharmacol 1996; 119: 1085-1092.